Status: Recruiting
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Participants needed: 96
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan YZY Biopharma Co., Ltd.Updated: May 14, 2026Locations: 1
Eligibility criteria
Males or females, aged > 18 years. [+8]
Patients with asymptomatic pleural fluid and not requiring clinical intervention... [+15]